NCT00654628View on ClinicalTrials.gov

Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)

PHASE4CompletedINTERVENTIONAL

Enrollment

173

Participants

Timeline

Start Date

August 1, 2007

Primary Completion Date

July 1, 2009

Study Completion Date

July 1, 2009

Conditions

Hypercholesterolemia

Interventions

DRUG

ezetimibe (+) simvastatin

Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00654628 - Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED) | Biotech Hunter | Biotech Hunter